Compared to TACSTD2-low, there was a greater prevalence of TP53 mutations in TACSTD2-high breast (59% vs 48%), colorectal (77% vs 71%), pancreatic (83% vs 69%), and liver cancer (43% vs 23%), but a lower prevalence in urothelial cancer (38% vs 54%). Here, TACSTD2 is linked to liver cancer.